Predicting high risk disease using serum and DNA biomarkers
Predicting high risk disease using serum and DNA biomarkers
复制标题
使用血清和 DNA 生物标志物预测高风险疾病
DOI：
10.1097/mou.0b013e32835f89b8
复制
发表时间：
2013
影响因子：
2.5
通讯作者：
R. Nam
中科院分区：
文献类型：
--
作者：
D. Vesprini;Stanley K. Liu;R. Nam
综述的目的：探讨几种基于血清和基因的生物标志物，通过预测那些有发展潜力或已经隐匿的高级别疾病，可能被证明对跟踪接受局部前列腺癌主动监测的男性有用。近年来越来越多的证据表明，血清生物标志物人钾激肽激酶2、早期前列腺癌抗原、尿激酶型纤溶酶原激活物/尿激酶型纤溶酶原激活物受体、转化生长因子-&bgr；1和白介素-6/白介素-6受体和遗传生物标志物BRCA1和BRCA2，磷酸酶和紧张素同源物，细胞髓细胞瘤癌基因和NKX3.1可能预测侵袭性高级别疾病，并在前列腺癌发生的早期可识别。对低风险、局限性前列腺癌广泛采用主动监测的一个障碍是，人们担心一些患者在诊断时可能隐藏着高风险疾病，或者发展成目前完善的预后因素无法检测到的更具侵袭性/不可治愈的疾病。本综述研究了几种血清和基于基因的生物标志物，这些生物标志物似乎对局限性前列腺癌有价值，而不像绝大多数更成熟的前列腺癌生物标志物，它们已经在更晚期的疾病中得到了验证。尽管讨论的生物标志物显示出令人兴奋的前景，但它们的临床应用尚不清楚，它们在主动监测场景中的作用需要进一步研究。
Purpose of review To explore several serum and genetic-based biomarkers that may prove useful in following men being managed with active surveillance for localized prostate cancer by predicting those that either have the potential to develop, or already harbor occult high grade disease. Recent findings There is increasing evidence that serum biomarkers human Kallikrein 2, early prostate cancer antigen, urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor, transforming growth factor-&bgr;1 and interleukin-6/interleukin-6 receptor and genetic biomarkers BRCA1 and BRCA2, Phosphatase and tensin homolog, cellular myelocytomatosis oncogene and NKX3.1 may predict for aggressive high grade disease and are identifiable early in prostate carcinogenesis. Summary One of the barriers of widespread adoption of active surveillance for low risk, localized prostate cancer is the concern that some patients may harbor occult high-risk disease at diagnosis, or develop more aggressive/noncurable disease not detected by our current well established prognostic factors. This review examines several serum and genetic-based biomarkers that appear to be of value in localized prostate cancer, unlike the vast majority of more established prostate cancer biomarkers that have been validated in far more advanced disease. Although the biomarkers discussed show exciting promise, their clinical utility is unknown, and their role in the active surveillance scenario needs further study.
登录
查看更多内容
影响因子：
7.5
作者：
Chapman, HA
通讯作者：
Chapman, HA
影响因子：
11.2
作者：
I. Kuzmin;J. Gillespie;A. Protopopov;L. Geil;K. Dreijerink;Youfeng Yang;C. Vocke;F. Duh;E. Zabar
通讯作者：
I. Kuzmin;J. Gillespie;A. Protopopov;L. Geil;K. Dreijerink;Youfeng Yang;C. Vocke;F. Duh;E. Zabar
影响因子：
6.6
作者：
Deras, Ina L.;Aubin, Sheila M. J.;Groskopf, Jack
通讯作者：
Groskopf, Jack
影响因子：
11.2
作者：
K. Cooney;Jon C. Wetzel;S. Merajver;Jill A. Macoska;T. Singleton;K. Wojno
通讯作者：
K. Cooney;Jon C. Wetzel;S. Merajver;Jill A. Macoska;T. Singleton;K. Wojno
影响因子：
45.3
作者：
Kattan, MW;Shariat, SF;Slawin, KM
通讯作者：
Slawin, KM